* exclusion from study enrollment includes meeting one or more of the following criteria: vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent. spo2 \< 94% on ambient air. active malignancy requiring treatment within the last five years. major surgery or physical trauma in the last 3 months, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries. all subjects with any comorbidities that may be associated with risk of progression to severe covid-19 including but not limited to renal dysfunction, hepatic disease, substance abuse, fibromyalgia, heart failure, uncontrolled arrhythmias, any level of dementia, depression, connective tissue diseases, major neuromuscular deficits, and endocrine disorders. subjects found to be at high risk for progression to severe covid-19 will be excluded from the study. these subjects will be referred to outpatient internal medicine clinic for sars-cov-2 monoclonal antibody treatment. as defined by the cdc and nih, high risk for progression to severe covid-19 is defined by meeting at least one of the following criteria: body mass index (bmi) \>35 have chronic kidney disease have diabetes have immunosuppressive disease are currently receiving immunosuppressive treatment are \>65 years of age are \>55 years of age and have cardiovascular disease, or hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease. patients who received sars-cov-2 monoclonal antibody treatment will be excluded from the study. vital sign abnormalities: temperature ≥ 38 °c, temperature \< 35 °c; systolic blood pressure (sbp) \< 90 mmhg, sbp ≥ 170 mmhg; diastolic blood pressure (dbp) \< 50 mmhg, dbp ≥ 100 mmhg; heart rate (hr) \< 50 beats per minute (bpm), hr ≥ 120 bpm. lab abnormalities: wbc ≥ 12,000 /μl, creatinine ≥ 1.5 mg/dl, ast ≥ 100 iu/l, and/or alt ≥ 100 iu/i patients who received covid-19 vaccination within last 28 days.

* exclusion from study enrollment includes meeting one or more of the following criteria: vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent. spo2 \< 94% on ambient air. active malignancy requiring treatment within the last five years. major surgery or physical trauma in the last 3 months, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries. all subjects with any comorbidities that may be associated with risk of progression to severe covid-19 including but not limited to renal dysfunction, hepatic disease, substance abuse, fibromyalgia, heart failure, uncontrolled arrhythmias, any level of dementia, depression, connective tissue diseases, major neuromuscular deficits, and endocrine disorders. subjects found to be at high risk for progression to severe covid-19 will be excluded from the study. these subjects will be referred to outpatient internal medicine clinic for sars-cov-2 monoclonal antibody treatment. as defined by the cdc and nih, high risk for progression to severe covid-19 is defined by meeting at least one of the following criteria: body mass index (bmi) \>35 have chronic kidney disease have diabetes have immunosuppressive disease are currently receiving immunosuppressive treatment are \>65 years of age are \>55 years of age and have cardiovascular disease, or hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease. patients who received sars-cov-2 monoclonal antibody treatment will be excluded from the study. vital sign abnormalities: temperature ≥ 38 °c, temperature \< 35 °c; systolic blood pressure (sbp) \< 90 mmhg, sbp ≥ 170 mmhg; diastolic blood pressure (dbp) \< 50 mmhg, dbp ≥ 100 mmhg; heart rate (hr) \< 50 beats per minute (bpm), hr ≥ 120 bpm. lab abnormalities: wbc ≥ 12,000 /μl, creatinine ≥ 1.5 mg/dl, ast ≥ 100 iu/l, and/or alt ≥ 100 iu/i patients who received covid-19 vaccination within last 28 days.

exclusion from study enrollment includes meeting one or more of the following criteria: vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent. spo2 < 94% on ambient air. active malignancy requiring treatment within the last five years. major surgery or physical trauma in the last 3 months, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries. all subjects with any comorbidities that may be associated with risk of progression to severe covid-19 including but not limited to renal dysfunction, hepatic disease, substance abuse, fibromyalgia, heart failure, uncontrolled arrhythmias, any level of dementia, depression, connective tissue diseases, major neuromuscular deficits, and endocrine disorders. subjects found to be at high risk for progression to severe covid-19 will be excluded from the study. these subjects will be referred to outpatient internal medicine clinic for sars-cov-2 monoclonal antibody treatment. as defined by the cdc and nih, high risk for progression to severe covid-19 is defined by meeting at least one of the following criteria: body mass index (bmi) >35 have chronic kidney disease have diabetes have immunosuppressive disease are currently receiving immunosuppressive treatment are >65 years of age are >55 years of age and have cardiovascular disease, or hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease. patients who received sars-cov-2 monoclonal antibody treatment will be excluded from the study. vital sign abnormalities: temperature ≥ 38 °c, temperature < 35 °c; systolic blood pressure (sbp) < 90 mmhg, sbp ≥ 170 mmhg; diastolic blood pressure (dbp) < 50 mmhg, dbp ≥ 100 mmhg; heart rate (hr) < 50 beats per minute (bpm), hr ≥ 120 bpm. lab abnormalities: wbc ≥ 12,000 /μl, creatinine ≥ 1.5 mg/dl, ast ≥ 100 iu/l, and/or alt ≥ 100 iu/i patients who received covid-19 vaccination within last 28 days.

exclusion from study enrollment includes meeting one or more of the following criteria: vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent. spo2 < 94% on ambient air. active malignancy requiring treatment within the last five years. major surgery or physical trauma in the last 3 months, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries. all subjects with any comorbidities that may be associated with risk of progression to severe covid-19 including but not limited to renal dysfunction, hepatic disease, substance abuse, fibromyalgia, heart failure, uncontrolled arrhythmias, any level of dementia, depression, connective tissue diseases, major neuromuscular deficits, and endocrine disorders. subjects found to be at high risk for progression to severe covid-19 will be excluded from the study. these subjects will be referred to outpatient internal medicine clinic for sars-cov-2 monoclonal antibody treatment. as defined by the cdc and nih, high risk for progression to severe covid-19 is defined by meeting at least one of the following criteria: body mass index (bmi) >35 have chronic kidney disease have diabetes have immunosuppressive disease are currently receiving immunosuppressive treatment are >65 years of age are >55 years of age and have cardiovascular disease, or hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease. patients who received sars-cov-2 monoclonal antibody treatment will be excluded from the study. vital sign abnormalities: temperature ≥ 38 °c, temperature < 35 °c; systolic blood pressure (sbp) < 90 mmhg, sbp ≥ 170 mmhg; diastolic blood pressure (dbp) < 50 mmhg, dbp ≥ 100 mmhg; heart rate (hr) < 50 beats per minute (bpm), hr ≥ 120 bpm. lab abnormalities: wbc ≥ 12,000 /μl, creatinine ≥ 1.5 mg/dl, ast ≥ 100 iu/l, and/or alt ≥ 100 iu/i patients who received covid-19 vaccination within last 28 days.